The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community

EANM Neuroimaging Comm, Valentina Garibotto*, Nathalie L. Albert, Henryk Barthel, Bart van Berckel, Ronald Boellaard, Matthias Brendel, Diego Cecchin, Ozgul Ekmekcioglu, Elsmarieke van de Giessen, Eric Guedj, Adriaan A. Lammerstma, Franck Semah, Tatjana Traub-Weidinger, Donatienne Van Weehaeghe, Silvia Morbelli

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)3033-3036
Number of pages4
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume48
Issue number10
Early online date17-Jul-2021
DOIs
Publication statusPublished - Sep-2021
Externally publishedYes

Keywords

  • AMYLOID-PET
  • BIOMARKERS
  • DEMENTIA
  • TRIALS

Cite this